UY35230A - Métodos y composiciones para administración de oxibutinina - Google Patents

Métodos y composiciones para administración de oxibutinina

Info

Publication number
UY35230A
UY35230A UY0001035230A UY35230A UY35230A UY 35230 A UY35230 A UY 35230A UY 0001035230 A UY0001035230 A UY 0001035230A UY 35230 A UY35230 A UY 35230A UY 35230 A UY35230 A UY 35230A
Authority
UY
Uruguay
Prior art keywords
salt
agents
compositions
methods
oxibutinine
Prior art date
Application number
UY0001035230A
Other languages
English (en)
Inventor
Cook Robert
David A Byron
Fleming Scott
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/728,706 external-priority patent/US9119777B2/en
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of UY35230A publication Critical patent/UY35230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para tratar la enfermedad pulmonar que comprende administrar directamente a los pulmones de un paciente una cantidad terapéuticamente efectiva en combinación con uno o más agentes farmacéuticamente efectivos. La oxibutinina se puede seleccionar del grupo formado por, en forma no taxativa, una sal de xinafoato, una sal de palmitato, una sal de pamoico, una sal de resonato, una sal de laurato y otras sales. Los agentes farmacéuticamente efectivos comprenden broncodilatadores, antiinflamatorios, corticosteroides, agentes de reversión de corticosteroides o agentes de crecimiento alveolar u otros agentes seleccionados de inhibidores de proteinasa o de proteasa.
UY0001035230A 2012-12-27 2013-12-20 Métodos y composiciones para administración de oxibutinina UY35230A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/728,706 US9119777B2 (en) 2008-05-30 2012-12-27 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
UY35230A true UY35230A (es) 2015-01-30

Family

ID=51021931

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035230A UY35230A (es) 2012-12-27 2013-12-20 Métodos y composiciones para administración de oxibutinina

Country Status (15)

Country Link
EP (1) EP2938329A4 (es)
JP (1) JP2016504358A (es)
KR (1) KR20150100902A (es)
CN (1) CN104955444A (es)
AR (1) AR094287A1 (es)
AU (1) AU2013368298B2 (es)
BR (1) BR112015015421A2 (es)
CA (1) CA2895955A1 (es)
EA (1) EA201591218A1 (es)
HK (2) HK1215396A1 (es)
IL (1) IL239623A0 (es)
MX (1) MX2015008333A (es)
NZ (1) NZ628479A (es)
UY (1) UY35230A (es)
WO (1) WO2014105446A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094626B1 (ko) * 2016-02-25 2020-03-27 히사미쓰 세이야꾸 가부시키가이샤 외용 액제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071108A2 (en) * 1999-05-20 2000-11-30 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
CA2498189A1 (en) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Quaternary ammonium compounds
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
AU2009241628A1 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP2012530134A (ja) * 2009-06-16 2012-11-29 タン，ウェン 呼吸器疾患治療における併用療法及び吸入薬剤としてのｒ型バンブテロールの使用
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
KR101730684B1 (ko) * 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말을 위한 담체 입자 제조 방법
CA2812952A1 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation

Also Published As

Publication number Publication date
AU2013368298B2 (en) 2016-08-11
NZ628479A (en) 2016-06-24
HK1216843A1 (zh) 2016-12-09
EP2938329A4 (en) 2016-08-10
AU2013368298A1 (en) 2015-07-02
HK1215396A1 (zh) 2016-08-26
AR094287A1 (es) 2015-07-22
MX2015008333A (es) 2015-11-09
WO2014105446A1 (en) 2014-07-03
EP2938329A1 (en) 2015-11-04
IL239623A0 (en) 2015-08-31
KR20150100902A (ko) 2015-09-02
CN104955444A (zh) 2015-09-30
JP2016504358A (ja) 2016-02-12
EA201591218A1 (ru) 2015-11-30
CA2895955A1 (en) 2014-07-03
BR112015015421A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
CO2020016582A2 (es) Sales de sepiapterina farmacéuticamente aceptables
BR112014010223A8 (pt) inibidores de reciclagem de ácido de bílis para o tratamento de doenças hepáticas colestáticas pediatras
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
CR20140086A (es) Tratamientos de combinación para hepatitis c
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112014029016A8 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
ECSP14007965A (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
BR112014004963A2 (pt) sal de colina do composto anti-inflamatório ciclobutanodiona substituído
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
BR112016024020A8 (pt) composição farmacêutica
BR112022000231A2 (pt) Novos métodos
GT201400042A (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210715